A two-year observational study in 164 treatment-experienced people living with HIV found that switching to doravirine-based regimens preserved high virological suppression while showing favorable metabolic and renal outcomes. The report supports doravirine’s role as a longer-term option in an era focused on maintaining suppression with improved tolerability. The study highlights renal and metabolic endpoints alongside virological control—an increasingly important package for clinicians managing multi-morbidity and long-term ART complications. Observational follow-up still carries inherent limitations versus randomized comparisons, but extended time horizons are valuable for assessing durability beyond short switching windows. For biotech stakeholders, the findings reinforce market positioning for agents with differentiated safety profiles. In practical terms, sustained suppression with fewer metabolic and kidney tradeoffs can influence prescribing behavior and guideline adoption. The main industry implication is that doravirine continues to show multi-system tolerability signals over time, which may translate into persistence and switching patterns in real-world care.
Get the Daily Brief